

October 21, 2024

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540, 890202

Scrip Code: SOLARA, SOLARAPP

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on October 21, 2024 and Submission of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024 as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

We wish to inform that meeting of Board of Directors of Solara Active Pharma Sciences Limited (“**Company**”) held today (i.e., Monday, the October 21, 2024), the Directors has inter-alia

- i. **Considered and Approved Unaudited financial results (Standalone and Consolidated)** of the Company for the quarter and half year ended September 30, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which was reviewed by the Audit Committee. A copy of the unaudited financial results (standalone and consolidated) along with the Limited Review Report by the Auditors and press release is attached.

Please note that aforesaid Financial Results will also be available on the Company's website at <https://solara.co.in/investor-relations/financial-information>.

- ii. **Allotment of Equity Shares Pursuant to Exercise of Options under Solara Employee Stock Option Plan 2018**

Pursuant to Regulation 30 read with Schedule III to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”) and Regulation 10(c) of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, (“**SEBI SBEB & SE Regulations**”), the Board of Directors had approved the allotment of 49,000 (Forty Nine Thousand Only) Equity Shares of face value Rs. 10/- each fully paid up against the exercise of vested Options of Solara Employee Stock Option Plan 2018.

The equity shares so allotted under the aforesaid Scheme, shall rank pari-passu with the existing equity shares of the Company in all respects. Consequent to the aforesaid allotment, the paid-up share capital of the Company will accordingly increase from ₹

Communication Address:

Solara Active Pharma Sciences Limited
2nd Floor, Admin Block
27, Vandaloor Kelambakkam Road,
Keelakottaiyur Village, Melakottaiyur (Post)
Chennai – 600 127, India
Tel: +91 44 43446700
Fax: +91 44 47406190
E-mail: investors@solara.co.in
www.solara.co.in

40,20,48,312.5/- (divided into 4,80,04,022 equity shares of ₹10/- each) to ₹ 40,25,38,312.50 (divided into 4,80,53,022 equity shares of ₹10/- each).

In terms of Regulation 10(c) read with Part – E of the SEBI SBEB & SE Regulations, the details of the shares allotted are enclosed herewith as "**Annexure-A**". and the details required under Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as "**Annexure -B**".

The Board Meeting commenced at 12.00 Noon and concluded at 13.45 pm.

We request you to take the same on record.

Thanking you,
Yours faithfully,

For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary

Encl.: As above

Annexure-A
Disclosure under Part E pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

Sl. No.	Particulars	Details
1	Company name and address of Registered Office	Solara Active Pharma Sciences Limited 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400703
2	Name of the Stock Exchange on which the company's shares are listed	1. National Stock Exchange of India Limited 2. BSE Limited
3	Filing date of the statement referred in Regulation 10(b) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognised Stock Exchange	• NSE: October 24, 2018 • BSE: October 24, 2018
4	Filing Number, if any	• NSE: NSE/LIST/19224 • BSE: DCS/IPO/JR/ESOPIP/3352/2018-19
5	Title of the Scheme pursuant to which shares are issued, if any	Solara Employee Stock Option Plan, 2018
6	Kind of security to be listed	Equity shares
7	Par value of the shares	₹10/- per Equity Share
8	Date of issue of shares	October 21, 2024
9	Number of shares issued	49,000 Equity Shares
10	Share Certificate No., if applicable	Not Applicable
11	Distinctive number of the share, if applicable:	48004023-48053022
12	ISIN Number of the shares if issued in Demat	INE624Z01016
13	Exercise price per share	Rs. 252/- and Rs. 292/-
14	Premium per share	Rs. 242/- and Rs. 282/-
15	Total issued shares after this issue	4,80,53,022 Equity Shares at Rs. 10/- each
16	Total issued share capital after this issue	₹ 40,25,38,312.50/-

17	Details of any lock-in on the shares	Not Applicable
18	Date of expiry of lock-in	Not Applicable
19	Whether shares are identical in all respects to existing shares? If not, when will they become identical?	Shares issued shall rank pari- pasu with the existing equity shares of the company
20	Details of listing fees, if payable	Not Applicable

Annexure – B

Sr. No.	Particulars	Details
1	Brief details of options granted	49,000 (Forty-Nine Only) Options granted under Solara Employee Stock Option Plan 2018
2	Whether the scheme is in terms of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ('SBEB & SE Regulations'), if applicable	Yes
3	Total number of shares covered by these options	49,000 (Forty-Nine Only) Equity Shares of face value of Rs. 10/- each to be issued against 49,000 (Forty-Nine Only) Options under Solara Employee Stock Option Plan 2018 upon exercise.
4	Pricing Formula/ Exercise Price	Exercise Price is Rs. 252/- and Rs. 292/-
5	Options Vested	49,000 options vested
6	Time within which options may be exercised	Options shall be exercised within 120 days from the date of Vesting of the Options within which an Employee should exercise his/ her right to apply for Shares against the vested Option in pursuance of the Plan. The Options shall not be permitted to be exercised

Communication Address:

Solara Active Pharma Sciences Limited
2nd Floor, Admin Block
27, Vandaloor Kelambakkam Road,
Keelakottaiyur Village, Melakottaiyur (Post)
Chennai – 600 127, India
Tel: +91 44 43446700
Fax: +91 44 47406190
E-mail: investors@solara.co.in
www.solara.co.in

		after the expiry of the above-mentioned Exercise Period
7	Options exercised	49,000 Options
8	Money realized by exercise of Options	Rs. 1,27,08,000/-
9	The Total number of shares arising as a result of exercise of Option	49,000 Equity Shares
10	Option lapsed	Not Applicable
11	Variation of terms of Options	Not Applicable
12	Brief details of significant terms	
13	Subsequent changes or cancellation or exercise of Option	Not Applicable
14	Diluted earnings per share pursuant to issue of equity shares on exercise of options. (Consol:H1 25)	Rs. (0.96/-)

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SOLARA ACTIVE PHARMA SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SOLARA ACTIVE PHARMA SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and six months ended September 30, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Sl. No.	Name of the entities
1	Solara Active Pharma Sciences Limited, the Parent
2	Shasun USA Inc., wholly-owned subsidiary
3	Chemsynth Laboratories Private Limited, subsidiary
4	Sequent Penems Private Limited, wholly-owned subsidiary (up to April 25, 2024)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte Haskins & Sells LLP

6. The consolidated unaudited financial results includes the interim financial information of 3 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 6.73 Crores as at September 30, 2024, total revenue of Rs. Nil and Rs. Nil for the quarter and six months ended September 30, 2024 respectively, total loss after tax of Rs. 0.02 Crores and Rs. 0.03 Crores for the quarter and six months ended September 30, 2024 respectively and total comprehensive loss of Rs. 0.02 Crores and Rs. 0.03 Crores for the quarter and six months ended September 30, 2024 respectively and cash inflows (net) of Rs. NIL for the six months ended September 30, 2024, as considered in the Statement.

According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Sandeep Kukreja
(Partner)
(Membership No. 220411)
(UDIN: 24220411BKERP7259)

Place: Bengaluru
Date: October 21, 2024



SOLARA ACTIVE PHARMA SCIENCES LIMITED

CIN: L24230MH2017PLC291436

Regd. Office: No. 201 Deavavra, Sector 17, Vashi, Navi Mumbai 400 703.

Address: 2nd Floor, Admin Block 27, Vandaloar kelambakkam Road, Keelakottaiyur Village, Chennai 600 127

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

(Rs. in Crores except per share data)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Revenue from operations	346.95	363.49	425.24	710.44	777.55	1,268.92
II	Other income	0.32	0.56	1.18	0.88	3.22	5.37
III	Total income (I + II)	347.27	364.05	426.42	711.32	780.77	1,274.29
IV	Expenses						
	(a) Cost of materials consumed	156.93	137.10	241.83	294.03	444.51	760.65
	(b) Purchases of stock-in-trade	0.70	-	3.12	0.70	4.70	5.10
	(c) Changes in inventories of finished goods, stock-in-trade and work in progress	14.26	64.47	(7.42)	78.73	(19.69)	39.27
	(d) Employee benefits expense	52.71	55.02	64.12	107.73	125.27	243.92
	(e) Finance costs	28.28	30.87	24.44	59.15	49.05	105.11
	(f) Depreciation and amortisation expense	25.34	25.07	26.21	50.41	52.12	103.33
	(g) Other expenses	61.04	64.98	85.96	126.02	166.01	335.16
	Total expenses (IV)	339.26	377.51	438.26	716.77	821.97	1,592.54
V	Profit/(loss) before exceptional items and tax (III - IV)	8.01	(13.46)	(11.84)	(5.45)	(41.20)	(298.25)
VI	Exceptional item profit / (loss) (Refer note 6)	-	-	(5.22)	-	(5.22)	(190.17)
VII	Profit/(loss) before tax (V - VI)	8.01	(13.46)	(17.06)	(5.45)	(46.42)	(488.42)
VIII	Tax expense						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	-	-	-	-	(10.25)	78.54
	Total tax expense (VIII)	-	-	-	-	(10.25)	78.54
IX	Profit/(loss) for the period (VII - VIII)	8.01	(13.46)	(17.06)	(5.45)	(36.17)	(566.96)
X	Other comprehensive income						
A	Items that will not be reclassified subsequently to profit or loss:						
	(i) Remeasurement gains/(losses) of defined benefit plans	1.70	-	0.24	1.70	0.24	0.56
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
B	Items that may be reclassified to subsequently to profit or loss:						
	(i) Exchange differences on translating the financial statements of foreign operations	(0.02)	(0.01)	(0.01)	(0.03)	(0.01)	(0.07)
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	-	-	-	-	-	-
	Total other comprehensive income for the period (X)	1.68	(0.01)	0.23	1.67	0.23	0.49
XI	Total comprehensive income/(loss) for the period (IX + X)	9.69	(13.47)	(16.83)	(3.78)	(35.94)	(566.47)
XII	Profit for the year attributable to:						
	- Equity shareholders of the Company	8.01	(13.46)	(17.16)	(5.45)	(36.71)	(567.39)
	- Non-controlling interests	-	-	0.10	-	0.54	0.43
XIII	Other Comprehensive income attributable to:						
	- Equity shareholders of the Company	1.68	(0.01)	0.23	1.67	0.23	0.49
	- Non-controlling interests	-	-	-	-	-	-
XIV	Total Comprehensive income attributable to:						
	- Equity shareholders of the Company	9.69	(13.47)	(16.93)	(3.78)	(36.48)	(566.90)
	- Non-controlling interests	-	-	0.10	-	0.54	0.43
XV	Paid-up equity share capital (face value of Rs. 10/- each)	40.21	40.21	36.00	40.21	36.00	36.00
XVI	Other equity excluding Non-controlling interest	-	-	-	-	-	897.91
	Earnings per equity share (face value of Rs. 10/- each) (not annualised for quarters)						
	(a) Basic (in Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)
	(b) Diluted (in Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)
	See accompanying notes to the consolidated financial results						



SOLARA ACTIVE PHARMA SCIENCES LIMITED
CIN: L24230MH2017PLC291636

Regd. Office: No. 201 Devavrala, Sector 17, Vashi, Navi Mumbai 400 703.

Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keelakottaiyur Village, Chennai 600 127
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

CONSOLIDATED BALANCE SHEET

(Rs. in Crores)

Sl. No.	Particulars	As at September 30, 2024 (UNAUDITED)	As at March 31, 2024 (AUDITED)
A	Assets		
I	Non-current assets		
	(a) Property, plant and equipment	768.11	805.66
	(b) Right of use assets	59.38	52.19
	(c) Capital work in progress	271.69	256.37
	(d) Investment property	2.33	2.39
	(e) Goodwill	364.90	365.09
	(f) Other intangible assets	36.07	42.56
	(g) Financial assets		
	(i) Investments	1.70	1.70
	(ii) Other financial assets	16.35	15.35
	(h) Income tax assets (net)	3.94	3.62
	(i) Other non-current assets	5.93	5.28
	Total non-current assets	1,530.40	1,550.21
II	Current assets		
	(a) Inventories	289.71	359.70
	(b) Financial assets		
	(i) Trade receivables	383.87	348.52
	(ii) Cash and cash equivalents	5.91	8.44
	(iii) Bank balances other than (ii) above	0.16	0.16
	(iv) Loans	0.04	0.34
	(v) Other financial assets	12.00	7.42
	(c) Other current assets	67.69	63.49
	(d) Assets classified as held for sale	-	12.68
	Total current assets	759.38	800.75
	Total Assets (I+II)	2,289.78	2,350.96
B	Equity and liabilities		
I	Equity		
	(a) Equity Share capital	40.21	36.00
	(b) Other equity	1,045.81	897.91
	Equity attributable to the owners of the Company	1,086.02	933.91
	Non-controlling interests	2.67	2.67
	Total Equity	1,088.69	936.58
II	Liabilities		
1	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	79.26	105.83
	(ii) Lease liabilities	18.06	11.61
	(iii) Other financial liabilities	0.42	0.42
	(b) Provisions	10.05	10.08
	(c) Other non-current liabilities	44.97	43.59
	Total Non-current liabilities	152.76	171.53
2	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	740.31	893.55
	(ii) Lease liabilities	2.32	0.51
	(iii) Trade payables		
	- Dues of micro and small enterprises	23.22	10.63
	- Dues of other than micro and small enterprises	258.05	302.38
	(iv) Other financial liabilities	14.49	13.52
	(b) Provisions	1.97	1.97
	(c) Current tax liabilities (net)	0.01	0.01
	(d) Other current liabilities	7.96	20.22
	(e) Liabilities directly associated with assets classified as held for sale	-	0.06
	Total current liabilities	1,048.33	1,242.85
	Total liabilities	1,201.09	1,414.38
	Total Equity and Liabilities (I+II)	2,289.78	2,350.96



SOLARA ACTIVE PHARMA SCIENCES LIMITED
CIN: L24230MH2017PLC291434

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keeiakottaiyur Village, Chennai 600 127

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

CONSOLIDATED STATEMENT OF CASH FLOWS

(Rs. In Crores)

Sl. No.	Particulars	Six months period ended 30-Sep-24	Six months period ended 30-Sep-23
		UNAUDITED	UNAUDITED
A	Cash flow from operating activities		
	Profit / (loss) before tax for the period	(5.45)	(46.42)
	Adjustments for:		
	Depreciation and amortisation	50.41	52.12
	Finance costs	59.15	49.05
	Share based compensation expenses (net of reversals)	1.02	(0.30)
	Rental income from investment property	(0.51)	(0.49)
	Interest income	(0.35)	(1.79)
	Liabilities / provisions no longer required written back	0.01	(0.02)
	Loss/(Profit) on sale of property, plant and equipment	(0.03)	(0.59)
	Impairment on assets classified as held for sale	-	5.22
	Provision for doubtful receivables and advances	1.37	5.50
	Unrealised exchange (gain)/loss (net)	(0.64)	0.32
	Operating cash flows before working capital changes	104.98	62.60
	Changes in working capital:		
	Adjustments for (increase) / decrease in operating assets:		
	Inventories	69.99	1.21
	Trade receivables	(36.59)	6.22
	Other assets (financial & non-financial)	(9.83)	(21.51)
	Adjustments for increase / (decrease) in operating liabilities:		
	Trade payables	(31.96)	42.05
	Other liabilities (financial & non-financial)	3.62	(2.90)
	Cash generated from operations	100.21	87.67
	Net income tax (paid) / refunds	(0.32)	(0.50)
	Net cash flow generated from operating activities (A)	99.89	87.17
B	Cash flow from investing activities		
	Capital expenditure for property, plant and equipments and intangible assets, including capital advances	(19.77)	(26.30)
	Proceeds from sale of property, plant and equipment	0.04	0.60
	Rental income from investment property	0.51	0.49
	Loan (given) / received	-	10.09
	Proceeds from sale of subsidiary	1.14	-
	Interest received	0.36	2.20
	Net cash flow utilised in investing activities (B)	(17.72)	(12.92)
C	Cash flow from financing activities		
	Proceeds from issue of equity shares	157.77	-
	Share issue expenses	(2.89)	-
	Proceeds from non-current borrowings	-	4.90
	Repayment of non-current borrowings	(60.14)	(60.87)
	Net increase / (decrease) in current borrowings	(119.06)	27.81
	Lease payments	(0.87)	(0.43)
	Finance costs	(59.51)	(48.09)
	Net cash flow generated from financing activities (C)	(84.70)	(76.68)
	Net increase in cash and cash equivalents (A+B+C)	(2.53)	(2.43)
	Cash and cash equivalents at the beginning of the period	8.44	8.73
	Cash and cash equivalents at the end of the period	5.91	6.30

Reconciliation of cash and cash equivalents with the Consolidated Balance Sheet

Particulars	As at 30-Sep-24	As at 30-Sep-23
Cash and cash equivalents as per Balance Sheet	5.91	6.30
Cash and cash equivalents at the end of the period*	5.91	6.30
* Comprises		
Cash on hand	0.03	0.09
Balance with banks:		
- In current account	3.13	3.36
- In deposit account	2.75	2.85
Total	5.91	6.30





SOLARA ACTIVE PHARMA SCIENCES LIMITED
CIN: L24230MH2017PLC291436

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Address: 2nd Floor, Admin Block 27, Vandaloar keiambakkam Road, Keelakottaiyur Village, Chennai 400 127

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

Notes:

- The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Parent" or the Company) and its subsidiaries (together referred to as "the group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on October 21, 2024. The results for the quarter and six months ended September 30, 2024 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified conclusion in respect of limited review for the quarter and six months ended September 30, 2024.
- These consolidated financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial results", prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder (IND AS) and other accounting principles generally accepted in India and in terms of the guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The group has incurred losses of Rs. 5.45 crores for the six months ended September 30, 2024 (Rs. 566.96 crores for the year ended March 31, 2024). The group's net current liabilities exceed its net current assets by Rs. 288.95 crores as at September 30, 2024.

To mitigate the situation and adequately fund its operations, the Parent has received a partial amount of Rs. 157.48 crores out of Rs. 449.95 crores from existing shareholders under the rights issue during the half year ended September 30, 2024, with the remaining funds of Rs. 292.47 crores to be called as needed. The group expects to renew its working capital facilities, as and when required, in the normal course of business and also increase revenues and margins on its products and accordingly expects to continue to have cash inflows from operations in amounts that are adequate enough to meet all future obligations as they fall due. Based on the above, the Board of directors have approved the preparation of the financial results on a going concern basis.
- The Group's operations relate to only one reportable segment viz Active Pharmaceutical Ingredient (API). Accordingly no separate disclosure of segment information is required.

5 Information on Standalone Financial Results:

(Rs. In Crores)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
i	Total Income	347.27	364.87	426.47	712.14	780.85	1,294.29
ii	Profit/(loss) before tax	8.02	(12.32)	(15.26)	(4.30)	(45.39)	(488.33)
iii	Profit/(loss) after tax	8.02	(12.32)	(15.26)	(4.30)	(35.14)	(566.87)

6 Exceptional item profit / (loss) :

(Rs. In Crores)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
i	Write off of Property, plant and equipment	-	-	(2.53)	-	(2.53)	(2.53)
ii	Impairment on assets classified as held for sale	-	-	(2.69)	-	(2.69)	(2.33)
iii	Exceptional loss on account of fire at Puducherry facility	-	-	-	-	-	(62.50)
iv	Write down of inventories relating to Covid/ anti-viral drugs	-	-	-	-	-	(122.81)
	Total	-	-	(5.22)	-	(5.22)	(190.17)

- The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 Equity shares of face value of Rs.10/- each at a price of Rs. 375/- per Equity share (including Share premium of Rs. 365/- per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e May 15, 2024. Rights issue has been done in accordance with Section 62(1)(a) of the Companies Act, 2013 and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on 19 June, 2024. Accordingly, the paid-up equity share capital of the Company has increased from Rs. 36,00,52,670/- divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs.10/- each to Rs.40,20,48,313/- divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs.10/- each and 1,19,98,755 partly paid up Equity Shares having face value of Rs. 10/- each with a paid up value of Rs. 3,50/- per share. Pursuant to the Rights issue, earnings per share (EPS) in respect of previous year / periods have been adjusted as per Indian Accounting Standard 33 "Earnings per share", prescribed under Section 133 of the Companies Act, 2013.
- The Board of the Parent Company has approved the transfer of 100% shareholding in Sequent Penems Private Limited, a wholly owned subsidiary, through a circular resolution dated March 22, 2024. The share purchase agreement was executed on March 28, 2024, for a cash consideration of Rs. 12.50 crores and shares were transferred on April 25, 2024.

Place : Bengaluru
Date: October 21, 2024

For and on behalf of board
Poorvank Purohit
Poorvank Purohit
MD & CEO
DIN: 10158900



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SOLARA ACTIVE PHARMA SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SOLARA ACTIVE PHARMA SCIENCES LIMITED** ("the Company"), for the quarter and six months ended September 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Sandeep Kukreja

(Partner)
(Membership No. 220411)
(UDIN: 24220411BKERPA4339)

Place: Bengaluru
Date: October 21, 2024



SOLARA ACTIVE PHARMA SCIENCES LIMITED
CIN: L24230MH2017PLC291636

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keelakottaiyur Village, Chennai 600 127

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

(Rs. in Crores except per share data)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Revenue from operations	346.95	363.49	425.24	710.44	777.55	1,288.92
II	Other income	0.32	1.38	1.23	1.70	3.30	5.37
III	Total Income (I + II)	347.27	364.87	426.47	712.14	780.85	1,294.29
IV	Expenses						
	(a) Cost of materials consumed	156.93	137.10	241.83	294.03	444.51	760.65
	(b) Purchases of stock-in-trade	0.70	-	3.12	0.70	4.70	5.10
	(c) Changes in inventories of finished goods, stock-in-trade and work in progress	14.26	64.47	(7.42)	78.73	(19.69)	39.27
	(d) Employee benefits expense	52.71	55.02	64.12	107.73	125.27	243.92
	(e) Finance costs	28.28	30.87	24.47	59.15	49.98	105.97
	(f) Depreciation and amortisation expenses	25.34	25.07	26.14	50.41	51.97	103.03
	(g) Other expenses	61.03	64.66	85.92	125.69	165.95	335.04
	Total expenses (IV)	339.25	377.19	438.18	716.44	822.69	1,592.98
V	Profit/(loss) before exceptional items and tax (III - IV)	8.02	(12.32)	(11.71)	(4.30)	(41.84)	(298.69)
VI	Exceptional item profit / (loss) (Refer note 5)	-	-	(3.55)	-	(3.55)	(189.64)
VII	Profit/(loss) before tax (V - VI)	8.02	(12.32)	(15.26)	(4.30)	(45.39)	(488.33)
VIII	Tax expense						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	-	-	-	-	(10.25)	78.54
	Total tax expense (VIII)	-	-	-	-	(10.25)	78.54
IX	Profit/(loss) for the period (VII - VIII)	8.02	(12.32)	(15.26)	(4.30)	(35.14)	(566.87)
X	Other comprehensive income						
A	Items that will not be reclassified subsequently to profit or loss:						
	(i) Remeasurement gains/(losses) of defined benefit plans	1.70	-	0.24	1.70	0.24	0.56
B	Items that may be reclassified to subsequently to profit or loss:						
	Income tax relating to items that may be reclassified to statement of profit and loss	-	-	-	-	-	-
	Total other comprehensive income/(loss) for the period (X)	1.70	-	0.24	1.70	0.24	0.56
XI	Total comprehensive income/(loss) for the period (IX + X)	9.72	(12.32)	(15.02)	(2.60)	(34.90)	(566.31)
XII	Paid-up equity share capital (face value of Rs. 10/- each)	40.21	40.21	36.00	40.21	36.00	36.00
XIII	Other equity						901.42
	Earnings per equity share (face value of Rs. 10/- each) (not annualised for quarters)						
	(a) Basic (in Rs.)	2.11	(3.20)	(3.99)	(1.09)	(9.20)	(148.38)
	(b) Diluted (in Rs.)	2.11	(3.20)	(3.99)	(1.09)	(9.20)	(148.38)
	See accompanying notes to the standalone financial results						



SOLARA ACTIVE PHARMA SCIENCES LIMITED

CIN: L24230MH2017PLC291434

Regd. Office: No. 201 Devavata, Sector 17, Vashi, Navi Mumbai 400 703.

Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keelakathayur Village, Chennai 600 127

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

STANDALONE BALANCE SHEET

(Rs. In Crores)

Sl. No.	Particulars	As at	As at
		September 30, 2024	March 31, 2024
		UNAUDITED	AUDITED
A	Assets		
I	Non-current assets		
	(a) Property, plant and equipment	761.51	799.05
	(b) Right of use assets	59.38	52.19
	(c) Capital work in progress	271.69	256.37
	(d) Investment property	2.33	2.39
	(e) Goodwill	364.90	364.90
	(f) Other intangible assets	36.07	42.56
	(g) Financial assets		
	(i) Investments	1.75	14.25
	(ii) Other financial assets	16.35	15.35
	(h) Income tax assets (net)	3.93	3.61
	(j) Other non-current assets	5.93	5.28
	Total non-current assets	1,523.84	1,555.95
II	Current assets		
	(a) Inventories	289.71	359.70
	(b) Financial assets		
	(i) Trade receivables	386.57	351.22
	(ii) Cash and cash equivalents	5.78	8.32
	(iii) Bank balances other than (ii) above	0.16	0.16
	(iv) Loans	0.04	0.34
	(v) Other financial assets	12.02	7.42
	(c) Other current assets	67.68	63.49
	Total current assets	761.96	790.65
	Total Assets (I+II)	2,285.80	2,346.60
B	Equity and liabilities		
I	Equity		
	(a) Equity share capital	40.21	36.00
	(b) Other equity	1,050.58	901.42
	Total equity	1,090.79	937.42
II	Liabilities		
1	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	79.26	105.83
	(ii) Lease liabilities	18.06	11.61
	(iii) Other financial liabilities	0.42	0.42
	(b) Provisions	10.05	10.08
	(c) Other non-current liabilities	44.97	43.59
	Total Non-current liabilities	152.76	171.53
2	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	740.31	893.55
	(ii) Lease liabilities	2.32	0.51
	(iii) Trade payables		
	- Dues of micro and small enterprises	23.22	10.63
	- Dues of other than micro and small enterprises	251.98	297.07
	(iv) Other financial liabilities	14.49	13.70
	(b) Provisions	1.97	1.97
	(c) Other current liabilities	7.96	20.22
	Total current liabilities	1,042.25	1,237.65
	Total liabilities	1,195.01	1,409.18
	Total equity and liabilities (I+II)	2,285.80	2,346.60



SOLARA ACTIVE PHARMA SCIENCES LIMITED

CIN: L24230MH2017PLC291636

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Address: 2nd Floor, Admin Block 27, Vandaloor Kelambakkam Road, Keelakattayur Village, Chennai 600 127

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

STANDALONE STATEMENT OF CASH FLOWS

(Rs. In Crores)

Sl. No.	Particulars	Six months period ended	Six months period ended
		30-Sep-24	30-Sep-23
		UNAUDITED	UNAUDITED
A	Cash flow from operating activities		
	Profit/(loss) before tax for the period	(4.30)	(45.39)
	Adjustments for:		
	Depreciation and amortisation	50.41	51.97
	Finance costs	59.15	49.98
	Share based compensation expenses (net of reversals)	1.02	(0.30)
	Rental income from investment property	(0.51)	(0.49)
	Interest income	(0.35)	(1.87)
	Liabilities / provisions no longer required written back	(0.81)	(0.02)
	Loss/(Profit) on sale of property, plant and equipment	(0.03)	(0.59)
	Write off of Property, plant and equipment	-	2.53
	Impairment on investments in subsidiary	-	1.02
	Provision for doubtful receivables and advances	1.37	5.50
	Unrealised exchange (gain)/loss (net)	(0.64)	0.33
	Operating cash flows before working capital changes	105.31	62.67
	Changes in working capital:		
	Adjustments for (increase) / decrease in operating assets:		
	Inventories	69.99	1.21
	Trade receivables	(36.59)	6.19
	Other assets (financial & non-financial)	(9.71)	(21.48)
	Adjustments for increase / (decrease) in operating liabilities:		
	Trade payables	(31.92)	41.97
	Other liabilities (financial & non-financial)	3.30	(2.90)
	Cash generated from operations	100.38	87.66
	Net income tax (paid) / refunds	(0.32)	(0.48)
	Net cash flow generated from operating activities (A)	100.06	87.18
B	Cash flow from investing activities		
	Capital expenditure for property, plant and equipments and intangible assets, including capital advances	(19.77)	(26.32)
	Proceeds from sale of property, plant and equipment	0.04	0.60
	Rental income from investment property	0.51	0.49
	Loan (given) / received	-	10.09
	Proceeds from sale of investments in other entities	0.96	-
	Interest received	0.36	2.25
	Net cash flow utilised in investing activities (B)	(17.90)	(12.89)
C	Cash flow from financing activities		
	Proceeds from issue of equity shares	157.77	-
	Share issue expenses	(2.89)	-
	Proceeds from non-current borrowings	-	4.90
	Repayment of non-current borrowings	(60.14)	(60.87)
	Net increase / (decrease) in current borrowings	(119.06)	27.81
	Lease payments	(0.87)	(0.43)
	Finance costs	(59.51)	(48.13)
	Net cash flow generated from financing activities (C)	(84.70)	(74.72)
	Net increase in cash and cash equivalents (A+B+C)	(2.54)	(2.43)
	Cash and cash equivalents at the beginning of the period	8.32	8.55
	Cash and cash equivalents at the end of the period	5.78	6.12

Reconciliation of cash and cash equivalents with the Standalone Balance Sheet:

Particulars	As at 30-Sep-24	As at 30-Sep-23
Cash and cash equivalents as per Balance Sheet	5.78	6.12
Cash and cash equivalents at the end of the period*	5.78	6.12
* Comprises		
Cash on hand	0.03	0.09
Balance with banks:		
- In current account	3.00	3.18
- In deposit account	2.75	2.85
Total	5.78	6.12





SOLARA ACTIVE PHARMA SCIENCES LIMITED
CIN: L24230MH2017PLC291434

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keelakattaiyur Village, Chennai 600 127

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

Notes:

- The above standalone financial results of Solara Active Pharma Sciences Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on October 21, 2024. The results for the quarter and half year ended September 30, 2024 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have issued unmodified conclusion in respect of the limited review for the quarter and half year ended September 30, 2024.
- These standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial results", prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and in terms of the guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The Company's operations relate to only one reportable segment viz Active Pharmaceutical Ingredient (API). Accordingly no separate disclosure of segment information is required.
- The Company has incurred losses of Rs. 4.30 crores for the half year ended September 30, 2024 (Rs. 566.87 crores for the year ended March 31, 2024). The Company net current liabilities exceed its net current assets by Rs. 280.29 crores as at September 30, 2024.

To mitigate the situation and adequately fund its operations, the Company has received a partial amount of Rs. 157.48 crores out of Rs. 449.95 crores from existing shareholders under the rights issue during the half year ended September 30, 2024, with the remaining funds of Rs. 292.47 crores to be called as needed. The Company expects to renew its working capital facilities, as and when required, in the normal course of business and also increase revenues and margins on its products and accordingly expects to continue to have cash inflows from operations in amounts that are adequate enough to meet all future obligations as they fall due. Based on the above, the Board of directors have approved the preparation of the financial results on a going concern basis.

5 Exceptional item profit / (loss) :

(Rs. In Crores)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Write off of Property, plant and equipment	-	-	(2.53)	-	(2.53)	(2.53)
II	Impairment on investments in Subsidiary	-	-	(1.02)	-	(1.02)	(1.80)
III	Exceptional loss on account of fire at Puducherry facility	-	-	-	-	-	(62.50)
IV	Write down of inventories relating to Covid/ anti-viral drugs	-	-	(3.55)	-	(3.55)	(122.81)
		-	-	(3.55)	-	(3.55)	(189.64)

- The Company, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 Equity shares of face value of Rs.10/- each at a price of Rs. 375 per Equity share (including Share premium of Rs. 365 per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Company on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e May 15, 2024. Rights issue has been done in accordance with Section 62(1)(g) of the Companies Act and other applicable laws. The Company has allotted 1,19,98,755 Nos. of partly paid up equity shares on 19 June, 2024.

Accordingly, the paid-up equity share capital of the Company has increased from Rs. 36,00,52,670 divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs.10 each to Rs. 40,20,48,313 divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs.10 each and 1,19,98,755 partly paid up Equity Shares having face value of Rs. 10 each. Pursuant to the Rights issue, earnings per share (EPS) in respect of previous year / periods have been adjusted as per Indian Accounting Standard 33 "Earnings per share", prescribed under Section 133 of the Companies Act, 2013.
- The Board of the Company has approved the transfer of 100% shareholding in Sequel Penems Private Limited, a wholly owned subsidiary, through a circular resolution dated March 22, 2024. The share purchase agreement was executed on March 28, 2024, for a cash consideration of Rs. 12.50 crores. The Company has a carrying value of investment in this subsidiary of Rs. 14.30 crores. Hence, the Company has accounted for an impairment on the investment in this subsidiary amounting to Rs. 1.80 crores during the previous year ended March 31, 2024. The shares were transferred on April 25, 2024.

For and on behalf of board

Poojank Purohit

Poojank Purohit
MD & CEO
DIN: 10158900

Place : Bengaluru
Date: October 21, 2024



Press Release

Solara reports a stronger Q2'25 performance

- **Solara reports Q2'25 Revenue at INR 3,472 Mn**
- **Gross margins at 50.5%; Significant improvement in Gross margins by 620 bps YoY and 600 bps QoQ returning to historical levels**
- **EBITDA at INR 616 Mn; with a growth of 46% QoQ and 61% YoY**
- **Positive PAT at INR 80 Mn**

Bengaluru, India – Oct 21, 2024: Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540), a leading Active Pharmaceutical Ingredient / CRAMS company, today announced the financial results for the second quarter (Q2'25)

Financial Performance for Q2'25

Particulars	Q2'25	Q1'25	QoQ%	Q2'24	YoY%	H1'25	H1'24	YoY%
Revenue	3,472	3,641	-5%	4,264	-19%	7,113	7,808	-9%
Gross margins	1,754	1,621	8%	1,891	-7%	3,375	3,503	-4%
Gross margins %	50.5%	44.5%	600 bps	44.3%	620 bps	47.4%	44.9%	250 bps
EBITDA	616	421	46%	382	61%	1,037	581	78%
EBITDA Margins %	17.7%	11.6%	610 bps	9.0%	870 bps	14.6%	7.4%	720 bps
PAT	80	(134)		(170)		(54)	(362)	

Commenting on the financial performance, **Poorvank Purohit**, MD & CEO of the Company, remarked, “We are pleased with the positive outcomes of the course correction measures which we had initiated for the Company. The stated plan to return to growth, enhance profitability and reduce debt has made significant headway. Our efforts on the course correction measures are leading to favourable outcomes resulting in significant margin expansion, in line with the management outlook. The Company reports a strong growth of 46% QoQ and 61% YoY on EBITDA with an improved EBITDA margin of 17.7%.

While our Revenues are down by 5% QoQ, our relentless focus on profitable growth resulted in Gross margins of 50.5%. Our Regulated market revenues continue to be at around 75% of total revenues. We are confident in continuing the growth momentum and are on track to continuously improving the quality of our earnings while strengthening our balance sheet.

Our ongoing actions on improving profitability through cost improvement programs, operating cost optimization, enhancing R&D productivity, optimizing working capital and debt will continue to yield benefits in the coming quarters.

We reaffirm our FY'25 outlook for Revenue of ~INR 15,000 Mn & the full year EBITDA of ~INR 2,300 to INR 2,600 Mn & Q4'25 exit quarter Revenue ~INR 4,000 Mn & EBITDA of ~INR 800 to INR 900 Mn with EBITDA margins of 20-22%”

More details are given in the Investor presentation.

EBITDA Reconciliation

Particulars (INR m)	Q2'25	Q1'25	Q2'24	H1'25	H1'24	FY24
Profit/loss) before exceptional items and tax	80	(134)	(118)	(54)	(412)	(2,976)
Add : Finance costs	283	307	244	590	490	1,048
Add: Depreciation and amortisation expense	253	251	262	504	521	1,033
Less: Interest income	-	(3)	(6)	(3)	(18)	(22)
Consolidated Reported EBITDA as per press release	616	421	382	1,037	581	(917)

Earnings Conference Call

The Company will conduct earnings call at **3.30 PM IST on October 21, 2024**, where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1346** or **+91 22 7115 8247**. Please note that the conference call transcript will be uploaded onto the Company website in due course.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA), headquartered in Bengaluru, India, offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 73 countries. It has a manufacturing base comprising six globally compliant API facilities, with approvals including the USFDA, EU GMP, and PMDA in Japan.

Investor / Analyst contact

Abhishek Singhal

✉ abhishek.singhal@solara.co.in

Statutory and corporate affairs

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

Disclaimer: Certain statements in this document are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



Solara reports a stronger Q2'25 performance

Q2 FY25 Results | Oct 21, 2024

Solara Active Pharma Sciences Limited

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Revenues

- ▶ Q2'25 Revenues at **INR 3,472 Mn**; Although revenues were marginally down QoQ, we are in line with outlook
- ▶ Revenues came in with improved Regulated market contribution
- ▶ Regulated markets contributed **76%** of Revenue vs. 71% in Q2'24

Gross margins

- ▶ Q2'25 Gross margins at **50.5%**; Significant improvement by 620 bps YoY and 600 bps QoQ, **returning to historical levels.**
- ▶ Improved Gross margins driven by higher Regulated market mix and focus on profitable products

Cost control measures

- ▶ Tight control on Operating costs
- ▶ Operating costs at INR 1,138 Mn in Q2'25; **down by INR 371 Mn YoY and INR 62 Mn QoQ**

EBITDA

- ▶ Q2'25 EBITDA at **INR 616 Mn**; grown by 61% YoY and 46% QoQ;
- ▶ Q2'25 EBITDA margins at **17.7%**; Significant improvement of 870 bps YoY and 610 bps QoQ, EBITDA expansion driven by improved Gross margins and tight control on Operating costs.
- ▶ EBITDA is **trending positively** towards the company's guided exit Q4 run-rate of 20-22%

Debt

- ▶ During H1'25, we reduced our Gross debt from INR 9,994 Mn to INR 8,195 Mn; a reduction of INR 1,799 Mn
- ▶ Q2'25 annualised Net Debt to EBITDA (adjusted for the uncalled Rights issue) is at **~2 times**. The Company is confident of beating the Net Debt to EBITDA outlook.

Compliance updates

- ▶ US FDA inspection was successfully completed at our Chennai R&D Centre with receipt of EIR from US FDA.
- ▶ Joint EUGMP inspection was successfully completed at Mangalore site with receipt of EUGMP Certificates from EDQM, Council of Europe & HPRA, Ireland
- ▶ EUGMP inspection was successfully completed at Puducherry site with receipt of EUGMP Certificate from Bavarian Authority, Germany

Performance (₹ In Million)

Gross margins nearing historical levels

Particulars	Q2'25	Q1'25	QoQ%	Q2'24	YoY%
Revenue	3,472	3,641	-5%	4,264	-19%
Gross margins	1,754	1,621	8%	1,891	-7%
Gross margins %	50.5%	44.5%	600 bps	44.3%	620 bps
Operating costs	1,138	1,200	-5%	1,509	-25%
EBITDA	616	421	46%	382	61%
EBITDA Margins %	17.7%	11.6%	610 bps	9.0%	870 bps
PAT	80	(134)		(170)	

PAT positive

EBITDA margins trending positively towards the outlook



Poorvank Purohit,
MD & CEO

We are pleased with the positive outcomes of the course correction measures which we had initiated for the Company. The stated plan to return to growth, enhance profitability and reduce debt has made significant headway. Our efforts on the course correction measures are leading to favourable outcomes resulting in significant margin expansion, in line with the management outlook. The Company reports a strong growth of 46% QoQ and 61% YoY on EBITDA with an improved EBITDA margin of 17.7%.


While our Revenues are down by 5% QoQ, our relentless focus on profitable growth resulted in Gross margins of 50.5%. Our Regulated market revenues continue to be at around 75% of total revenues. We are confident in continuing the growth momentum and are on track to continuously improving the quality of our earnings while strengthening our balance sheet.

Our ongoing actions on improving profitability through cost improvement programs, operating cost optimization, enhancing R&D productivity, optimizing working capital and debt will continue to yield benefits in the coming quarters.


We reaffirm our FY'25 outlook for Revenue of ~INR 15,000 Mn & the full year EBITDA of ~INR 2,300 to INR 2,600 Mn & Q4'25 exit quarter Revenue ~INR 4,000 Mn & EBITDA of ~INR 800 to INR 900 Mn with EBITDA margins of 20-22%




Revenues (₹ Million) and Gross margins (%)



Regulated market Revenues (₹ Million)



Operating Cost (₹ Million)



- While revenues dropped, margins have improved in our pursuit of profitable growth.
- A Calibrated approach focusing on profitability and free cash generation.
- Improved quality of earnings over the last four quarters with more focus on Regulated markets.
- Regulated market revenues at 76% of total Revenues reaching historical levels.
- Improved Gross margins driven by higher regulated market mix and focus on profitable products.
- Focus on Cost control and Cost Improvement programs through alternate vendors to achieve improved COGS.
- Reduced operating cost over the last four quarters to set right the operating cost structure.

Q2'25 QoQ and YoY Performance (₹ In Million)

Particulars	Q2'25	Q1'25	Change	Q2'24	Change
Revenue	3,472	3,641	-5%	4,264	-19%
Gross Margins	1,754	1,621	8%	1,891	-7%
Gross margins %	50.5%	44.5%	600 bps	44.3%	620 bps
Operating cost	1,138	1,200	-5%	1,509	-25%
EBITDA	616	421	46%	382	61%
EBITDA Margins %	17.7%	11.6%	610 bps	9.0%	870 bps
Exceptional items (gain)/loss	-	-		52	
Depreciation	253	251		262	
Finance cost (net)	283	304		238	
PAT	80	(134)		(170)	

- Regulated market constitutes 76% of our total revenues (Q1'25 - 76%; Q2'24 – 71%)
- Gross margins at 50.5%, up by 600 bps QoQ and 620 bps YoY driven by improved Regulated market mix and our continued focus on profitable products and cost improvement programs.
- EBITDA margins at 17.7%, up by 610 bps QoQ and 870 bps YoY

H1'25 YoY Performance (₹ In Million)

Particulars	H1'25	H1'24	Change
Revenue	7,113	7,808	-9%
Gross Margins	3,375	3,503	-4%
Gross margins %	47.4%	44.9%	250 bps
Operating cost	2,338	2,922	-20%
EBITDA	1,037	581	78%
EBITDA Margins %	14.6%	7.4%	720 bps
Exceptional items (gain)/loss	-	52	
Depreciation	504	521	
Finance cost (net)	587	472	
PAT	(54)	(362)	

- Regulated market constitutes 76% of our total revenues (H1'24 – 70%)
- Gross margins at 47.4% up by 250 bps YoY
- EBITDA margins at 14.6% up by 720 bps YoY
- Our ongoing actions on improving profitability through cost improvement programs, operating cost optimization, enhancing R&D productivity, optimizing working capital and debt will yield benefits in the coming quarters.

FY25 Outlook

H1'25 Performance

Update on FY25 Outlook

Revenue

₹ 15,000m+

₹ 7,113m

On track to achieve outlook

EBITDA

₹ 2,300m-₹ 2,600m

₹ 1,037m

On track to achieve outlook

EBITDA margins

15%-17%

14.6%

Trending positively towards achieving outlook

Q4'25 Exit Quarter Outlook

Q2'25 Performance

Update on Q4'25 Exit Quarter Outlook

Revenue

₹ 4,000m+

₹ 3,472m

On track to achieve outlook

EBITDA

₹ 800m-₹ 900m

₹ 616m

On track to achieve outlook

EBITDA margins

20%-22%

17.7%

Trending positively towards achieving outlook

Net Debt to EBITDA

<3 times

~2 times

Q2'25 annualised Net Debt to EBITDA (adjusted for the uncalled Rights issue) is at ~2 times. Significantly ahead of the outlook.

Sources of funds (₹ In Million)

Particulars	Mar'24	Sep'24
Shareholders' funds	9,339	10,858
Less: Goodwill	-3,651	-3,649
Net worth	5,688	7,209
Term Loan	2,391	1,791
Working capital Loan	7,603	6,404
Gross Debt	9,994	8,195
Total	15,682	15,404

Use of funds (₹ In Million)

Particulars	Mar'24	Sep'24
Net Tangible Fixed Assets	11,166	11,012
Net Non-current Assets	1	(136)
Net Current Assets	4,515	4,528
Total	15,682	15,404

Net Debt (₹ In Million)

Particulars	Amount (Rs. Mn)
Gross Debt as on 1.4.2024	9,994
Less: Repayment from operations	(613)
Less: Repayment from Rights issue application money	(1,186)
Gross Debt as on 30.09.2024	8,195
Less: Repayment for rest of the year	(994)
Less: Uncalled Rights issue money in which 75% will be used for debt repayment	(2,216)
Net Debt by end of FY25 after adjusting for Uncalled Rights issue money	4,985

- ▶ During the quarter, we reduced our Gross debt from INR 9,994 Mn to INR 8,195 Mn; a reduction of INR 1,799 Mn.
- ▶ Out of the total Rights issue of INR 449.95 Crores, INR 157.48 Crores was received by way of Application money. 75% of the Rights money was obligated to be used for repayment of existing debt. Accordingly, the Company had repaid INR 1,186 Mn towards repayment of existing debt from the Rights issue. The balance amount of debt reduction of INR 613 Mn was repaid from the normal business operations.
- ▶ After adjusting for the uncalled Rights Issue money in which 75% will be used for debt repayment (INR 2,216 Mn), our targeted net debt by end of FY25 will be under ~INR 5,000 Mn.

Adjusted Net Debt to EBITDA (adjusted for the Uncalled Rights issue money) trending at ~ 2 times based on Q2'25 EBITDA exit run-rate.

Retrofitting Vizag to predominantly a large multipurpose CRAMS facility including High Potent APIs (HPAPIs)

- Vizag facility is among our largest manufacturing sites and successfully concluded USFDA inspection in May'24 with zero 483 observations, a similar outcome as its previous inspection.
- Since then, the facility has been mothballed and is being retrofitted to predominately focus on increased opportunities on CRAMS, High Potent APIs (HPAPIs) and to meet our increased demand on polymer-based APIs.
- It will continue to be a second site for Ibuprofen while we focus on utilizing our capacities fully in our flagship Puducherry facility for Ibuprofen and its derivatives.
- Capex for retrofitting Vizag will be funded from internal accruals
- **We expect the facility to return to commercial production by Q1 FY26.**

Thank you